How safe is Stem Cell Therapy for Parkinson’s Disease?
Stem cell therapy with mesenchymal stromal cells (MSCs) given by intravenous (IV) infusion has shown a favorable safety profile in people with Parkinson's disease.

A phase 1 trial published in Movement Disorders (Schiess and colleagues, 2021) gave single IV infusions of donor MSCs at increasing doses to people with mild to moderate Parkinson's, and the infusions were safe and well tolerated, with no serious adverse events attributed to the cells. Across many conditions, the most consistent side effect of IV MSCs is a temporary fever. Parkinson's itself, however, creates specific safety considerations: low blood pressure on standing, falls, swallowing difficulties, sensitivity to sedation and certain drug interactions, and the need to keep medication schedules exact. These are managed through careful screening and planning. At Stem Cell Mexico, Parkinson's protocols use allogeneic MSCs from umbilical cord tissue, usually by IV infusion, which avoids brain surgery. Surgical cell replacement, a different and more invasive approach, is currently limited to clinical trials.
This guide explains what is known about safety, the Parkinson's-specific risks to plan for and how they are reduced.
Two approaches with different safety profiles
Supportive MSC therapy (IV infusion)
- No surgery; cells circulate and act through anti-inflammatory and neurotrophic signals.
- Most common effects: temporary fever, headache or fatigue.
- Serious complications uncommon in controlled studies.
Dopamine cell replacement (neurosurgery)
- Dopamine neuron precursors grown from pluripotent stem cells are implanted into the brain.
- A 2025 phase 1 trial in Nature (Tabar and colleagues) with 12 patients met its safety goals, with no adverse events attributed to the cells and no graft-induced involuntary movements through 18 months. Adverse events that did occur were related to surgery or unrelated illness.
- Carries neurosurgical risks such as bleeding, infection and seizures, and requires immunosuppression in some protocols.
- Available only in clinical trials.
Historical experiences with fetal tissue transplants, in which some patients developed troublesome involuntary movements, shaped today's careful approach to cell replacement.
What the evidence shows for MSC safety
- Parkinson's-specific: the Schiess phase 1 trial reported that IV allogeneic bone-marrow MSCs were safe across escalating doses, with exploratory signals of benefit at the highest dose. A subsequent randomized trial by the same group has studied efficacy further.
- Across conditions: a 2026 systematic review in Stem Cells Translational Medicine (Hum and colleagues) of 42 randomized trials with 2,280 patients receiving intravascular umbilical cord MSCs found more temporary fever, with no signals of harm for infection, thrombosis, malignancy, abnormal tissue formation or death, while recommending continued long-term monitoring.
What a temporary fever can mean in Parkinson's
Fever is the most common side effect of IV MSCs, usually mild and lasting one to two days. In Parkinson's, any fever or illness can temporarily make symptoms worse: movements may feel slower, "off" periods may be longer, and some people become more confused or sleepy. This usually improves as the temperature returns to normal. Staying hydrated, continuing medications on time and treating fever with paracetamol help. A high or persistent fever, or fever with cough, painful urination or confusion that does not improve, should be checked promptly, because infections such as pneumonia or urinary tract infections are a common cause of sudden worsening in Parkinson's and need specific treatment.
Parkinson's-specific safety considerations
Medication timing
Levodopa and other Parkinson's medications must be taken on schedule. Missing or delaying doses during travel, fasting or procedures can cause severe stiffness, immobility and, rarely, a dangerous reaction similar to neuroleptic malignant syndrome. Your plan should specify exactly how doses are handled on the procedure day; Parkinson's medications should not be stopped without your neurologist's guidance.
Low blood pressure on standing (orthostatic hypotension)
Common in Parkinson's and worsened by fasting, dehydration, travel and some medications. It increases the risk of dizziness and falls. Fluids, slow position changes and monitoring are part of the plan.
Falls
Balance problems and freezing of gait increase fall risk in unfamiliar places. Assistance with transfers, clear pathways and a companion help.
Swallowing and sedation
Swallowing difficulties increase the risk of aspiration, especially with sedation. IV infusions usually do not require sedation; if sedation is needed for another procedure, it is planned carefully.
Confusion and hallucinations
Some people with Parkinson's become confused or have hallucinations in new environments, with sleep disruption or with certain medications. Keeping routines, good lighting and family presence helps.
Drug interactions
Some Parkinson's medications interact with drugs used around procedures. For example, MAO-B inhibitors such as rasagiline, selegiline and safinamide can interact dangerously with certain pain medications, including tramadol and meperidine, and with some other drugs. Because tramadol is sometimes suggested as an alternative to anti-inflammatory painkillers before cell treatment, people taking MAO-B inhibitors must tell the team so a safe pain plan, usually paracetamol, can be chosen. Certain anti-nausea and antipsychotic drugs that block dopamine should also be avoided.
Deep brain stimulation (DBS)
Patients with DBS devices should bring device information. Most IV procedures do not interfere with DBS, but some equipment and imaging require precautions.
The role of caregivers and family
Many people with Parkinson's rely on a spouse, child or caregiver for medication reminders, mobility support and communication with doctors. Involving that person in the evaluation and treatment plan improves safety. Caregivers can help keep medication schedules exact during travel, notice early signs of confusion or dehydration, assist with transfers and report changes after treatment. They also tend to observe gradual changes in movement, speech or energy more accurately than the patient. If you will travel alone, let the team know so additional support can be arranged.
How we reduce risk
- Neurology record review: diagnosis, stage, symptoms, medication list with exact timing, DBS status and history of falls, hallucinations or swallowing problems.
- Medication safety plan: maintaining Parkinson's medication schedules and avoiding interacting drugs.
- Pre-treatment testing: complete blood count, metabolic panel, urinalysis and tumor markers.
- Quality-controlled cells: donor screening, infectious disease testing, and laboratory quality testing before release.
- Monitoring of blood pressure, including standing measurements when appropriate, heart rate, temperature and oxygen during and after infusion.
- Fall prevention: assistance, accessible rooms and companion support.
- Observation with nursing supervision.
Long-term safety
Most MSC studies in Parkinson's have followed patients for months to about a year, and broader analyses across conditions have not shown increased rates of cancer, abnormal tissue growth or serious infections. Because Parkinson's is a long-term condition and new symptoms will naturally appear over time, continued neurological follow-up helps separate disease progression from any effect of treatment.
Safety and benefit are separate questions
MSC therapy appears safe in Parkinson's studies, and its effects on symptoms vary between patients. According to the U.S. National Institute of Neurological Disorders and Stroke (NINDS), medications, deep brain stimulation for selected patients, and exercise and therapy remain the foundation of care. MSC therapy is offered as a supportive option alongside that care.
Regulatory context
No stem cell therapy is approved by the FDA or the European Medicines Agency for Parkinson's disease. In Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS. Ask for documentation of cells and facility.
Who may be a safe candidate
- Confirmed Parkinson's disease (not atypical parkinsonism) with stable symptoms.
- Manageable blood pressure and fall risk.
- No significant swallowing problems that would make the stay unsafe.
- No active infection and no cancer within the past five years.
- A companion or caregiver available when needed.
- Realistic goals and willingness to continue neurological care, exercise and therapy.
Preparing for treatment
Bring a medication list with exact doses and times, and enough medication for the whole trip plus extra. Keep taking your Parkinson's medications on schedule unless instructed otherwise. Tell the team about MAO-B inhibitors, DBS, dizziness on standing, falls, hallucinations and swallowing problems. Arrive a day early if possible, drink fluids as allowed, and plan rest. Record a short baseline video of walking and tremor to compare later.
Signs to report after treatment
Seek prompt care for high or persistent fever, severe stiffness or inability to move, confusion or new hallucinations, fainting or falls, difficulty swallowing or breathing, or chest pain.
Questions to ask during your evaluation
- Is this supportive MSC therapy or cell replacement, and what are the specific risks?
- How will my medication schedule be maintained on treatment day?
- Which pain medications are safe with my Parkinson's drugs?
- How will dizziness and fall risk be managed?
- How will you coordinate with my neurologist?
Bottom line
IV MSC therapy for Parkinson's disease has shown a favorable safety profile in early trials, with temporary fever as the most common side effect. Safety depends on maintaining medication schedules, avoiding drug interactions, preventing falls and managing blood pressure and swallowing risks. A medical evaluation can help determine whether this type of regenerative treatment is appropriate and safe for your symptoms, medications and medical history.
References
- Schiess M et al. Allogeneic bone marrow-derived mesenchymal stem cell safety in idiopathic Parkinson's disease. Movement Disorders, 2021 (opens in a new tab)
- Tabar V et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson's disease. Nature, 2025 (opens in a new tab)
- National Institute of Neurological Disorders and Stroke (NINDS, NIH): Parkinson's disease (opens in a new tab)
- Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
